Related references
Note: Only part of the references are listed.Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma
Pier Luigi Zinzani et al.
CLINICAL LYMPHOMA & MYELOMA (2007)
Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate
Jennifer M. Levine et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2006)
Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients
P. L. Zinzani et al.
ANNALS OF ONCOLOGY (2006)
Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma
Melissa M. Rhodes et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2006)
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
M Hutchings et al.
BLOOD (2006)
FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma
NG Mikhaeel et al.
ANNALS OF ONCOLOGY (2005)
Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma
M Hutchings et al.
ANNALS OF ONCOLOGY (2005)
18F-FDG PET in malignant lymphoma:: significance of positive findings
P Castellucci et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2005)
FDG-PET in the clinical management of Hodgkin lymphoma
M Hutchings et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2004)
Follicular lymphoma international prognostic index
P Solal-Céligny et al.
BLOOD (2004)
FDG pet in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy
WC Lavely et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2003)
Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma
RH Blum et al.
CLINICAL LYMPHOMA (2003)
Positron emission tomography with [18F]FDG for therapy response monitoring in lymphoma patients
Karoline Spaepen et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma
Christiaan Schiepers et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease
G Jerusalem et al.
ANNALS OF ONCOLOGY (2003)
Positron emission tomography for the staging of Hodgkin's lymphoma -: Increasing the body of evidence in favor of the method
C Menzel et al.
ACTA ONCOLOGICA (2002)
Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma
M Sasaki et al.
ANNALS OF NUCLEAR MEDICINE (2002)
Advantages of positron emission tomography (PET) with respect to computed tomography in the follow-up of lymphoma patients with abdominal presentation
PL Zinzani et al.
LEUKEMIA & LYMPHOMA (2002)
Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease
MR Weihrauch et al.
ANNALS OF HEMATOLOGY (2002)
Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma
A Wirth et al.
AMERICAN JOURNAL OF MEDICINE (2002)
Can positron emission tomography with [18F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?
K Spaepen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma-comparison with CT
NG Mikhaeel et al.
LEUKEMIA & LYMPHOMA (2000)
Share Paper
